

Shelly A Mcneil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212405/publications.pdf>

Version: 2024-02-01

176
papers

8,549
citations

46918

47
h-index

53109

85
g-index

177
all docs

177
docs citations

177
times ranked

8955
citing authors

#	ARTICLE	IF	CITATIONS
1	The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. <i>Clinical Infectious Diseases</i> , 2022, 74, 1459-1467.	2.9	41
2	COVID-19 outbreaks in acute and long-term care: Conceptualizing patterns of vulnerability and benefits of interventions. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100312.	3.0	2
3	Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. <i>Vaccine</i> , 2022, 40, 2635-2646.	1.7	6
4	Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 744-752.	1.3	30
5	Persistent Functional Decline Following Hospitalization with Influenza or Acute Respiratory Illness. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 696-703.	1.3	34
6	Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective. <i>Vaccine</i> , 2021, 39, A36-A41.	1.7	5
7	An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study. <i>Vaccine</i> , 2021, 39, 3397-3403.	1.7	6
8	Centenarians and extremely old people living with frailty can elicit durable SARS-CoV-2 spike specific IgG antibodies with virus neutralization functions following virus infection as determined by serological study. <i>EClinicalMedicine</i> , 2021, 37, 100975.	3.2	6
9	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€”Part 1: Live Vaccines. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e59-e71.	0.1	6
10	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€”Part 2: Inactivated Vaccines. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e72-e91.	0.1	8
11	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€”Part 2: Inactivated Vaccines. <i>Gastroenterology</i> , 2021, 161, 681-700.	0.6	14
12	Patient perspectives of pain mitigation strategies for adult vaccine injections. <i>Canadian Journal of Pain</i> , 2021, 5, 183-191.	0.6	2
13	Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)â€”Part 1: Live Vaccines. <i>Gastroenterology</i> , 2021, 161, 669-680.e0.	0.6	11
14	Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: a Phase III, Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 181-190.	2.9	104
15	Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020, 71, 1022-1029.	2.9	19
16	Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. <i>Vaccine</i> , 2020, 38, 1384-1392.	1.7	53
17	Are healthcare personnel at higher risk of seasonal influenza than other working adults?. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 267-272.	1.0	1
18	A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18â€”50 Years of Age. <i>Vaccines</i> , 2020, 8, 393.	2.1	7

#	ARTICLE	IF	CITATIONS
19	Performance of a Modified Two-Tiered Testing Enzyme Immunoassay Algorithm for Serologic Diagnosis of Lyme Disease in Nova Scotia. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	8
20	Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000550.	1.2	21
21	Influenza surveillance case definitions miss a substantial proportion of older adults hospitalized with laboratory-confirmed influenza: A report from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 499-504.	1.0	15
22	Pharmacists as immunizers to <u>Improve</u> coverage and provider/recipient satisfaction: <u>A</u> prospective, <u>C</u>ontrolled <u>C</u>ommunity <u>E</u>mbedded <u>S</u>tudy with vaccine<u>S</u> with low coverage rates (the Improve ACCESS Study): Study summary and anticipated significance. <i>Canadian Pharmacists Journal</i> , 2020, 153, 88-94.	0.4	6
23	Complicated hospitalization due to influenza: results from the Global Hospital Influenza Network for the 2017-2018 season. <i>BMC Infectious Diseases</i> , 2020, 20, 465.	1.3	29
24	Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada. <i>Emerging Infectious Diseases</i> , 2020, 26, 454-462.	2.0	1
25	Frailty Hinders Recovery From Influenza and Acute Respiratory Illness in Older Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 428-437.	1.9	34
26	Influenza Vaccination: Accelerating the Process for New Vaccine Development in Older Adults. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2020, 43, 98-112.	2.6	6
27	Exploring Clinically Meaningful Changes for the Frailty Index in a Longitudinal Cohort of Hospitalized Older Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1928-1934.	1.7	41
28	Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults. <i>Journal of Medical Microbiology</i> , 2020, 69, 256-264.	0.7	6
29	COVID-19, frailty and long-term care: Implications for policy and practice. <i>Journal of Infection in Developing Countries</i> , 2020, 14, 428-432.	0.5	42
30	Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1231-1238.	1.7	36
31	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 988-1000.	4.6	136
32	Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1001-1012.	4.6	25
33	Long-Term Care Admissions Following Hospitalization: The Role of Social Vulnerability. <i>Healthcare (Switzerland)</i> , 2019, 7, 91.	1.0	13
34	<i>Streptococcus pneumoniae</i> serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN). <i>Vaccine</i> , 2019, 37, 5466-5473.	1.7	29
35	Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD. <i>Chest</i> , 2019, 155, 69-78.	0.4	67
36	Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. <i>Vaccine</i> , 2019, 37, 6262-6267.	1.7	18

#	ARTICLE	IF	CITATIONS
37	Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine. <i>Journal of Infectious Diseases</i> , 2019, 219, 1799-1803.	1.9	9
38	Which healthcare workers work with acute respiratory illness? Evidence from Canadian acute-care hospitals during 4 influenza seasons: 2010–2011 to 2013–2014. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 889-896.	1.0	24
39	Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2865-2872.	1.4	22
40	Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). <i>BMC Public Health</i> , 2019, 19, 487.	1.2	33
41	Preventing Infections and Healthy Aging. , 2019, , 181-188.		1
42	Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. <i>Vaccine</i> , 2019, 37, 2482-2493.	1.7	34
43	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. <i>Cancer</i> , 2019, 125, 1301-1312.	2.0	68
44	Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. <i>Drugs and Aging</i> , 2019, 36, 29-37.	1.3	60
45	Reply to Skowronski et al. <i>Journal of Infectious Diseases</i> , 2018, 217, 169-169.	1.9	0
46	Factors associated with influenza vaccination among healthcare workers in acute care hospitals in Canada. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 319-325.	1.5	16
47	A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. <i>Journal of Infectious Diseases</i> , 2018, 218, 378-387.	1.9	39
48	Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). <i>Vaccine</i> , 2018, 36, 2166-2175.	1.7	52
49	PCR-based discrimination of emerging <i>Streptococcus pneumoniae</i> serotypes 22F and 33F. <i>Journal of Microbiological Methods</i> , 2018, 144, 99-106.	0.7	6
50	Florid Granuloma Annulare–Like Reaction in Regional Lymph Nodes After “Regression” of Red Pigment in Tattoos. <i>American Journal of Dermatopathology</i> , 2018, 40, 383-385.	0.3	1
51	Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network. <i>Influenza and Other Respiratory Viruses</i> , 2018, 12, 232-240.	1.5	28
52	Pharmacists’ immunization experiences, beliefs, and attitudes in New Brunswick, Canada. <i>Pharmacy Practice</i> , 2018, 16, 1310.	0.8	15
53	149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S9-S10.	0.4	4
54	Multi-target plasmid controls for conventional and real-time PCR-based serotyping of <i>Streptococcus pneumoniae</i> . <i>Plasmid</i> , 2018, 98, 45-51.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Seasonal influenza immunisation: Strategies for older adults. <i>International Journal of Clinical Practice</i> , 2018, 72, e13249.	0.8	27
56	Comparison of response rates on invitation mode of a web-based survey on influenza vaccine adverse events among healthcare workers: a pilot study. <i>BMC Medical Research Methodology</i> , 2018, 18, 59.	1.4	13
57	A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response. <i>Clinical Infectious Diseases</i> , 2018, 67, 1063-1071.	2.9	84
58	Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05–2013/14, Toronto, Canada. <i>Antiviral Research</i> , 2017, 140, 158-163.	1.9	6
59	Active Surveillance for Influenza Reduces but Does Not Eliminate Hospital Exposure to Patients With Influenza. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 387-392.	1.0	6
60	Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1687.	3.8	12
61	Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. <i>Cmaj</i> , 2017, 189, E819-E827.	0.9	67
62	Multiplex Respiratory Virus Testing for Antimicrobial Stewardship: A Prospective Assessment of Antimicrobial Use and Clinical Outcomes Among Hospitalized Adults. <i>Journal of Infectious Diseases</i> , 2017, 216, 936-944.	1.9	55
63	Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. <i>Vaccine</i> , 2017, 35, 3647-3654.	1.7	26
64	Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1711-1719.	1.9	22
65	Assessing the diagnostic accuracy of PCR-based detection of <i>Streptococcus pneumoniae</i> from nasopharyngeal swabs collected for viral studies in Canadian adults hospitalised with community-acquired pneumonia: a Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research (CIRN) study. <i>BMJ Open</i> , 2017, 7, e015008.	0.8	6
66	Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. <i>Vaccine</i> , 2017, 35, 1764-1769.	1.7	36
67	Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults. <i>Vaccine</i> , 2017, 35, 6269-6274.	1.7	22
68	T-cell Phenotypes Predictive of Frailty and Mortality in Elderly Nursing Home Residents. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 153-159.	1.3	46
69	A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. <i>Journal of Infectious Diseases</i> , 2017, 215, 24-33.	1.9	58
70	The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People. <i>Journal of Infectious Diseases</i> , 2017, 216, 405-414.	1.9	133
71	Test-Negative Design: The Importance of Laboratory-Confirmed Illness in Estimating the Effectiveness of Influenza Vaccine in Older Adults. <i>Journal of Infectious Diseases</i> , 2017, 216, 399-401.	1.9	3
72	Frailty Hinders Recovery From Acute Respiratory Illness in Older Adults. <i>Open Forum Infectious Diseases</i> , 2017, 4, S573-S574.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada. <i>BMC Infectious Diseases</i> , 2017, 17, 805.	1.3	21
74	Refining PCR-based serotyping for detection of vaccine-preventable <i>Streptococcus pneumoniae</i> . <i>Journal of Epidemiological Research</i> , 2016, 3, .	0.6	3
75	A Retrospective Study of the Clinical Burden of Hospitalized All-Cause and Pneumococcal Pneumonia in Canada. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-10.	0.8	23
76	The Burden of Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease in Hospitalized Adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
77	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1154-1168.	4.6	148
78	Impact of pharmacists as immunizers on influenza vaccination coverage in Nova Scotia, Canada. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1225-1228.	1.4	27
79	Effect of package insert language on health-care providers' perceptions of influenza vaccination safety during pregnancy. <i>The Lancet Global Health</i> , 2016, 4, e690-e691.	2.9	19
80	Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and <i>post-hoc</i> correlate of protection analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3043-3055.	1.4	5
81	CMKLR1 activation <i>ex vivo</i> does not increase proportionally to serum total chemerin in obese humans. <i>Endocrine Connections</i> , 2016, 5, 70-81.	0.8	16
82	Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. <i>New England Journal of Medicine</i> , 2016, 375, 1019-1032.	13.9	752
83	Impact of pharmacists as immunizers on influenza vaccination coverage in the community-setting in Nova Scotia, Canada: 2013-2015. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 32.	1.1	15
84	Immunizing Patients With Adverse Events After Immunization and Potential Contraindications to Immunization. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e384-e391.	1.1	15
85	Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. <i>Journal of Infectious Diseases</i> , 2016, 214, 525-536.	1.9	36
86	Knowledge, attitudes, beliefs, and behaviors of pregnant women approached to participate in a Tdap maternal immunization randomized, controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 879-885.	1.4	30
87	Routine immunization of adults by pharmacists: Attitudes and beliefs of the Canadian public and health care providers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 623-631.	1.4	39
88	Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. <i>International Journal of Cancer</i> , 2016, 138, 2428-2438.	2.3	80
89	Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories. <i>Vaccine Journal</i> , 2016, 23, 236-242.	3.2	55
90	Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers. <i>Vaccine</i> , 2015, 33, 6635-6640.	1.7	13

#	ARTICLE	IF	CITATIONS
91	The challenge of vaccinating adults: attitudes and beliefs of the Canadian public and healthcare providers. <i>BMJ Open</i> , 2015, 5, e009062.	0.8	69
92	Detection and prediction of <i>Streptococcus pneumoniae</i> serotypes directly from nasopharyngeal swabs using PCR. <i>Journal of Medical Microbiology</i> , 2015, 64, 836-844.	0.7	19
93	Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 242-251.	0.6	28
94	Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial. <i>Vaccine</i> , 2015, 33, 559-567.	1.7	14
95	Pharmacists as immunizers: a survey of community pharmacists' willingness to administer adult immunizations. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 292-295.	1.0	31
96	A New Approach to Improving Healthcare Personnel Influenza Immunization Programs: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0118368.	1.1	9
97	Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. <i>Eurosurveillance</i> , 2015, 20, 21024.	3.9	48
98	A retrospective study of the clinical burden of hospitalized all-cause and pneumococcal pneumonia in Canada. <i>Canadian Respiratory Journal</i> , 2015, . .	0.8	1
99	Effects of a Pharmacy-Driven Perisplenectomy Vaccination Program on Vaccination Rates and Adherence to Guidelines. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 262-7.	0.1	6
100	H1N1 influenza vaccination during pregnancy. <i>BMJ</i> , The, 2014, 348, g3500-g3500.	3.0	1
101	Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness. <i>Journal of Infectious Diseases</i> , 2014, 209, 1873-1881.	1.9	206
102	Influenza symptoms and their impact on elderly adults: randomised trial of adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 452-462.	1.5	24
103	Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 33-42.	0.6	22
104	Maintaining the momentum: Key factors influencing acceptance of influenza vaccination among pregnant women following the H1N1 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3629-3641.	1.4	15
105	Rates and determinants of seasonal influenza vaccination in pregnancy and association with neonatal outcomes. <i>Cmaj</i> , 2014, 186, E157-E164.	0.9	94
106	Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. <i>BMC Public Health</i> , 2014, 14, 442.	1.2	55
107	Approved but non-funded vaccines: Accessing individual protection. <i>Vaccine</i> , 2014, 32, 766-770.	1.7	18
108	Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. <i>Vaccine</i> , 2014, 32, 624-630.	1.7	28

#	ARTICLE	IF	CITATIONS
109	Immune Biomarkers Predictive of Respiratory Viral Infection in Elderly Nursing Home Residents. PLoS ONE, 2014, 9, e108481.	1.1	43
110	AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infectious Diseases, The, 2013, 13, 485-496.	4.6	143
111	Influenza vaccination and fetal and neonatal outcomes. Expert Review of Vaccines, 2013, 12, 1417-1430.	2.0	26
112	Risk Factors for Influenza among Health Care Workers during 2009 Pandemic, Toronto, Ontario, Canada. Emerging Infectious Diseases, 2013, 19, 606-615.	2.0	32
113	Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children. Journal of Infectious Diseases, 2013, 208, 544-553.	1.9	62
114	Varicella-Zoster Virus-Specific Antibody Responses in 50-59-Year-Old Recipients of Zoster Vaccine. Journal of Infectious Diseases, 2013, 208, 1386-1390.	1.9	41
115	Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women. JAMA - Journal of the American Medical Association, 2013, 309, 1793.	3.8	352
116	Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered) Tj ETQq0 0 0 rgBT /Overlock 10 T licensed hepatitis B vaccine. Human Vaccines and Immunotherapeutics, 2013, 9, 1438-1444.	1.4	20
117	Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. Human Vaccines and Immunotherapeutics, 2013, 9, 2460-2473.	1.4	43
118	Epidemiology and Outcome of Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals. PLoS ONE, 2013, 8, e75171.	1.1	37
119	Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years. Clinical Infectious Diseases, 2012, 54, 922-928.	2.9	388
120	The authors respond. Cmaj, 2012, 184, 1926.4-1927.	0.9	0
121	The Role of Atypical Pathogens in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 244-256.	0.8	21
122	Safety and Immunogenicity of 2 Mixed Primary Infant Immunization Schedules of Pentavalent Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, and Haemophilus influenzae Type b Vaccines at 2, 4, and 6 Months of Age. Pediatric Infectious Disease Journal, 2012, 31, 189-192.	1.1	8
123	The Association Between Influenza Vaccine in Pregnancy and Adverse Neonatal Outcomes. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 714-720.	0.3	36
124	A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine. Vaccine, 2012, 30, 6287-6293.	1.7	31
125	Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine, 2012, 30, 974-982.	1.7	47
126	Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine, 2012, 30, 2556-2563.	1.7	107

#	ARTICLE	IF	CITATIONS
127	Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. <i>Vaccine</i> , 2012, 30, 2831-2838.	1.7	29
128	Safety and immunogenicity of 2010-2011 H1N1/2009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N1/2009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study. <i>Vaccine</i> , 2012, 30, 3389-3394.	1.7	15
129	Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate) Tj ETQq1 1 0.784314 ngBT /Overback 10	1.3	15
130	A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. <i>BMC Infectious Diseases</i> , 2012, 12, 279.	1.3	15
131	Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine. <i>PLoS ONE</i> , 2012, 7, e38563.	1.1	16
132	Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. <i>Vaccine</i> , 2011, 29, 8459-8465.	1.7	40
133	A(H1N1) pandemic influenza and its prevention by vaccination: Paediatricians' opinions before and after the beginning of the vaccination campaign. <i>BMC Public Health</i> , 2011, 11, 128.	1.2	7
134	An Incremental Economic Evaluation of Targeted and Universal Influenza Vaccination in Pregnant Women. <i>Canadian Journal of Public Health</i> , 2011, 102, 445-450.	1.1	23
135	Effect of respiratory hospitalization during pregnancy on infant outcomes. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, S54-S57.	0.7	95
136	Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial. <i>Vaccine Journal</i> , 2011, 18, 418-423.	3.2	49
137	Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2083-2091.	1.3	28
138	Acute otitis media and its prevention by immunization: A survey of Canadian pediatricians' knowledge, attitudes and beliefs. <i>Hum Vaccin</i> , 2011, 7, 429-435.	2.4	5
139	Kinetics of the Antibody Response to Tetanus-Diphtheria-Acellular Pertussis Vaccine in Women of Childbearing Age and Postpartum Women. <i>Clinical Infectious Diseases</i> , 2011, 53, 885-892.	2.9	139
140	Canadian family physicians' and paediatricians' knowledge, attitudes and practices regarding A(H1N1) pandemic vaccine. <i>BMC Research Notes</i> , 2010, 3, 102.	0.6	28
141	THE VAXED PROJECT: An Assessment of Immunization Education in Canadian Health Professional Programs. <i>BMC Medical Education</i> , 2010, 10, 86.	1.0	54
142	A Population-Based Evaluation of a Publicly Funded, School-Based HPV Vaccine Program in British Columbia, Canada: Parental Factors Associated with HPV Vaccine Receipt. <i>PLoS Medicine</i> , 2010, 7, e1000270.	3.9	181
143	Hepatitis A and travel amongst Nova Scotia postsecondary students: Evidence for a targeted vs. universal immunization strategy. <i>Vaccine</i> , 2010, 28, 8105-8111.	1.7	7
144	Routine Immunization of Adults in Canada: Review of the Epidemiology of Vaccine-Preventable Diseases and Current Recommendations for Primary Prevention. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009, 20, e81-e90.	0.7	21

#	ARTICLE	IF	CITATIONS
145	Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 186-193.	1.1	58
146	Pfannenstiel Incision Closure: A Review of Current Skin Closure Techniques. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2009, 31, 514-520.	0.3	17
147	Influenza in Pregnancy: The Case for Prevention. <i>Advances in Experimental Medicine and Biology</i> , 2009, 634, 161-183.	0.8	10
148	Setting priorities for new vaccination programs by using public health officers and immunization managers opinions. <i>Vaccine</i> , 2008, 26, 4204-4209.	1.7	10
149	Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 173-84.	3.8	194
150	Intention of parents to have male children vaccinated with the human papillomavirus vaccine. <i>Sexually Transmitted Infections</i> , 2008, 84, 318-323.	0.8	42
151	Influenza Vaccination and Decisional Conflict among Regulated and Unregulated Direct Nursing Care Providers in Long-Term Care Homes. <i>AAOHN Journal</i> , 2008, 56, 77-84.	0.5	3
152	Q Fever Update, Maritime Canada. <i>Emerging Infectious Diseases</i> , 2008, 14, 67-69.	2.0	11
153	Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. <i>Cmaj</i> , 2007, 176, 463-468.	0.9	382
154	Parental intention to have daughters receive the human papillomavirus vaccine. <i>Cmaj</i> , 2007, 177, 1506-1512.	0.9	132
155	Influenza Vaccine Programs and Pregnancy: New Canadian Evidence for Immunization. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007, 29, 674-676.	0.3	7
156	Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. <i>Vaccine</i> , 2007, 25, 3464-3474.	1.7	27
157	Vaccination against human papillomavirus: A baseline survey of Canadian clinicians' knowledge, attitudes and beliefs. <i>Vaccine</i> , 2007, 25, 7841-7847.	1.7	65
158	Core Competencies for Immunization Providers in Canada: A Multidisciplinary Priority. <i>Canadian Pharmacists Journal</i> , 2007, 140, S19-S19.	0.4	0
159	A double-blind, randomized phase II trial of the safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults. <i>International Congress Series</i> , 2006, 1289, 303-306.	0.2	19
160	Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. <i>Vaccine</i> , 2006, 24, 20-26.	1.7	118
161	Safety and immunogenicity of a Proteosome, -trivalent inactivated influenza vaccine, given nasally to healthy adults. <i>Vaccine</i> , 2006, 24, 1601-1608.	1.7	35
162	Influenza Vaccination. <i>Canadian Journal of Public Health</i> , 2006, 97, 136-138.	1.1	3

#	ARTICLE	IF	CITATIONS
163	Vancomycin-Resistant Enterococcal Colonization and Infection in Liver Transplant Candidates and Recipients: A Prospective Surveillance Study. <i>Clinical Infectious Diseases</i> , 2006, 42, 195-203.	2.9	128
164	Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers. <i>Clinical Infectious Diseases</i> , 2005, 41, 1114-1122.	2.9	271
165	Rates of influenza vaccination in older adults and factors associated with vaccine use: A secondary analysis of the Canadian Study of Health and Aging. <i>BMC Public Health</i> , 2004, 4, 36.	1.2	84
166	Influenza Vaccine Programs and Pregnancy: A Need for More Evidence. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2004, 26, 961-963.	0.3	5
167	Introduction of a Waterless Alcohol-Based Hand Rub in a Long-Term Care Facility. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 165-171.	1.0	78
168	Mupirocin-Based Decolonization of Staphylococcus aureus Carriers in Residents of 2 Long-Term Care Facilities: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2003, 37, 1467-1474.	2.9	147
169	Antimicrobials in Acute Exacerbations of Chronic Obstructive Pulmonary Disease - An Analysis of the Time to Next Exacerbation Before and After Implementation of Standing Orders. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2003, 14, 254-259.	0.3	4
170	Candida albicans Sternal Wound Infections: A Chronic and Recurrent Complication of Median Sternotomy. <i>Clinical Infectious Diseases</i> , 2002, 35, 1316-1320.	2.9	55
171	Endogenous Aspergillus Endophthalmitis. <i>Medicine (United States)</i> , 2002, 81, 311-320.	0.4	43
172	Risk Factors for Anaerobic Bloodstream Infections in Bone Marrow Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2001, 33, 338-343.	2.9	99
173	Effect of Hand Cleansing with Antimicrobial Soap or Alcohol-Based Gel on Microbial Colonization of Artificial Fingernails Worn by Health Care Workers. <i>Clinical Infectious Diseases</i> , 2001, 32, 367-372.	2.9	140
174	Outbreak of Sternal Surgical Site Infections Due to Pseudomonas aeruginosa Traced to a Scrub Nurse with Onychomycosis. <i>Clinical Infectious Diseases</i> , 2001, 33, 317-323.	2.9	67
175	Successful Treatment of Vancomycin-Resistant Enterococcus faecium Bacteremia with Linezolid after Failure of Treatment with Synercid (Quinupristin/Dalfopristin). <i>Clinical Infectious Diseases</i> , 2000, 30, 403-404.	2.9	51
176	Pathogenic Organisms Associated with Artificial Fingernails Worn by Healthcare Workers. <i>Infection Control and Hospital Epidemiology</i> , 2000, 21, 505-509.	1.0	112